Kura Oncology, Inc. (KURA) vs Pacira BioSciences, Inc. (PCRX)
A side-by-side comparison of Kura Oncology, Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KURA
Kura Oncology, Inc.
$10.79HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
PCRX
Pacira BioSciences, Inc.
$25.13HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT
Total return — KURA vs PCRX
growth of $100 · dividends reinvested · last 10yKURA +85.0% (+6.3%/yr)PCRX -27.9% (-3.2%/yr)KURA compounded faster over this window
KURA PCRX
KURA vs PCRX: by the numbers
- •PCRX is the larger company ($988M vs $958M market cap).
- •PCRX is profitable (1.96% net margin) while KURA runs a net loss (-384.30%).
Metrics side by side
Valuation
| Metric | KURA | PCRX |
|---|---|---|
| P/E ratio | N/A | 71.52 |
| P/S ratio | 12.40 | 1.32 |
| P/B ratio | 19.78 | 1.47 |
| EV / EBITDA | N/A | 11.53 |
| FCF yield | N/A | 18.16% |
Profitability
| Metric | KURA | PCRX |
|---|---|---|
| Gross margin | 94.73% | 79.21% |
| Operating margin | -449.94% | 2.47% |
| Net margin | -384.30% | 1.96% |
| ROE | -612.78% | 2.18% |
| ROIC | -67.13% | 1.35% |
Growth (annualized)
| Metric | KURA | PCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.20% |
| EPS CAGR (5Y) | N/A | -45.77% |
| FCF CAGR (5Y) | N/A | 16.72% |
| Total return CAGR (5Y) | -10.73% | -12.27% |
Frequently asked
- Is KURA or PCRX more profitable?
- PCRX runs the higher net margin — KURA at -384.30% versus PCRX at 1.96%.
- How have KURA and PCRX total returns compared?
- Over the past 10 years, KURA delivered 5.98% and PCRX delivered -3.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Pacira BioSciences P/E ratioKura Oncology ROEPacira BioSciences ROEKura Oncology operating marginPacira BioSciences operating marginKura Oncology revenue growthPacira BioSciences revenue growthKura Oncology free cash flowPacira BioSciences free cash flow
Kura Oncology & Pacira BioSciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.